QuatRx lands $44M in fifth round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
QuatRx
|
$44M
|
Venrock |
The money is earmarked for the completion of a Phase III and Phase II study of its two endocrine programs. There's also an early-stage trial of a lipid-lowering compound. |
|
Arete Therapeutics
|
$35M
|
Frazier Healthcare Ventures and Alta Partners |
Arete is developing drugs for cardiovascular, inflammatory and metabolic diseases. |
|
Biolex Therapeutics
|
$30M
|
Investor Growth Capital |
Biolex is advancing Locteron into Phase III clinical development in hepatitis C. |
|
Intrexon
|
$25M
|
New River Management |
The money has been earmarked to fund the company's pre-clinical work in gene-based therapies. |
|
Talima Therapeutics
|
$19M
|
US Venture Partners and Latterell Venture Partners |
The funding will allow the company to proceed through Phase II clinical trials. |